Modality
Radioligand
MOA
KRASG12Ci
Target
CD3
Pathway
Notch
Heart FailurePBC
Development Pipeline
Preclinical
Sep 2018
→ May 2028
PreclinicalCurrent
NCT05775709
1,765 pts·Heart Failure
2018-09→2028-05·Active
1,765 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-122.1y awayInterim· Heart Failure
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Active
Catalysts
Interim
2028-05-12 · 2.1y away
Heart Failure
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05775709 | Preclinical | Heart Failure | Active | 1765 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |